Anaphylatoxin formation in extracorporeal circuits.
Anaphylatoxin radioimmunoassay techniques have been employed to define both the temporal profile and the amount of complement activation taking place in two different types of extracorporeal circuits. Prospective studies of patients undergoing both maintenance hemodialysis and cardiopulmonary bypass provided essentially similar findings. In both cases, plasma C3a antigen levels proved to be the most accurate and sensitive indicator of intravascular complement activation. By contrast, plasma C5a levels varied little during the period of extracorporeal circulation. Instead, this anaphylatoxin retained considerable biologic activity in vivo as evidenced by its ability to promote granulocyte activation and transient granulocytopenia which was displayed by patients in both groups. Plasma levels of C4a antigen were not elevated during the period of extracorporeal circulation, suggesting that alternative pathway mechanisms were predominantly responsible for the complement activation taking place in both hemodialyzers and bypass oxygenators. However, classical pathway activation events could be documented when protamine sulfate was administered to heparinized patients after cardiopulmonary bypass. In this instance, elevated plasma levels of both C4a and C3a antigens were observed. Prospective studies also suggested that complement activation could be associated with the development of both acute and delayed clinical sequelae. Available data support the hypothesis that C5a anaphylatoxin might be the primary mediator of these undesirable effects of extracorporeal circulation. These types of investigations have contributed significantly to our understanding of the role of the anaphylatoxins in human disease and may be directly applied to facilitate design of more biocompatible medical devices.
D000706:Anaphylatoxins / Q000378:metabolism*; D006348:Cardiac Surgical Procedures; D003167:Complement Activation; D003176:Complement C3 / Q000032:analysis; D015926:Complement C3a; D003181:Complement C4 / Q000032:analysis; D015934:Complement C4a; D003182:Complement C5 / Q000032:analysis; D015936:Complement C5a; D005112:Extracorporeal Circulation; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D010455:Peptides / Q000378:metabolism*; D011446:Prospective Studies; D011863:Radioimmunoassay; D006435:Renal Dialysis
D000706:Anaphylatoxins; D003176:Complement C3; D003181:Complement C4; D003182:Complement C5; D010455:Peptides; D015926:Complement C3a; D015934:Complement C4a; D015936:Complement C5a